Astellas Pharma to Buy Iveric Bio
Wall Street Journal
The Japanese drugmaker said it agreed to acquire Iveric bio for about $5.9 billion to strengthen its capabilities in the ophthalmology field.
https://www.wsj.com/articles/astellas-pharma-to-buy-iveric-bio-for-about-5-9b-2d67408e